In New Zealand, prescription of GnRHa for gender dysphoria started around 2011; prevalence of use increased to 2014, then more steeply to 2022, followed by a decline. Incidence data show the decline started from 2021. New Zealand, compared to the Netherlands (which started prescribing in the 1990s), had 1.7 times the cumulative incidence of first prescriptions by 2018. Compared to England and Wales up to 2020, New Zealand had 3.5–6.9 times the cumulative incidence.
Levesque et al.’s widely-cited five dimensional model of access to healthcare has been used in a variety of contexts, including access to medicines.
The objective of the study is to conduct a systematic review and methodological quality appraisal on studies reporting the development of health and wellbeing outcome measures for Māori (Indigenous people of New Zealand), identify common features and processes, and critically appraise the measures using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN).
Prominent medical bodies are calling on the government to allow the release of updated gender affirming healthcare guidelines after a small section on puberty blockers caused it to be delayed.
HEALTH SERVICES AND SYSTEMS
EQUITY
Exploring the impacts of the health system on minorities within the population, notably including Māori, Pacifica, Asians and LGBTQI.
DRUGS, DEVICE AND DIAGNOSTICS
PUBLIC HEALTH
DIGITAL HEALTH
TE TIRITI